<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04853069</url>
  </required_header>
  <id_info>
    <org_study_id>MRC-05-099</org_study_id>
    <nct_id>NCT04853069</nct_id>
  </id_info>
  <brief_title>Oestrogen Treatment for COVID-19 Symptoms</brief_title>
  <official_title>The Impact of Oestrogen Administration on Covid-19 Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamad Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laboratoires Besins International</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hamad Medical Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to determine whether oestrogen treatment mitigates disease&#xD;
      progression and severity in confirmed COVID19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is known that (i) women are relatively protected from the impacts of other respiratory&#xD;
      viruses, and that oestrogen may partly mediate this effect (ii) Oestrogen protects rodents&#xD;
      from SARS-CoV-1 related mortality (iii) Women are relatively protected from developing or&#xD;
      dying from severe COVID-19 and (iv) Postmenopausal women taking oestrogen replacement appear&#xD;
      less likely to suffer Covid19-related critical illness. These effects may be mediated through&#xD;
      oestrogen-related immunomodulation. In addition, however, 17β estradiol reduces expression of&#xD;
      ACE2 (the receptor protein through which SARS-CoV-2 gains cellular entry) in tissues such as&#xD;
      the kidney. As such, supplemental oestrogen may represent an effective therapy for Covid19.&#xD;
&#xD;
      We will randomise adult men and postmenopausal women with confirmed Covid19 disease to&#xD;
      receive 10 days of transdermal oestrogen (3mg/day). The primary endpoint will be evidence of&#xD;
      disease progression, indicated by hospitalisation (mild cases) or need for mechanical&#xD;
      ventilation or death within 28 days of randomisation for those hospiatlsied. Secondary&#xD;
      outcomes will include hospital mortality, duration of hospital admission, admission to ICU/&#xD;
      HDU facility, ICU/ HDU length of stay, need for renal replacement therapy, receipt and&#xD;
      duration of invasive mechanical ventilation, cause-specific mortality and time to being fit&#xD;
      for hospital discharge&#xD;
&#xD;
      .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 17, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open label, randomized controlled trial, with patients randomized 1:1 to usual care, or usual care + oestrogen therapy.&#xD;
Prior to enrolment, an online CRF will be completed which will confirm that the patient meets the inclusion and exclusion criteria. Randomisation will be undertaken by the statistician in Qatar. Separate randomisation codes will be allocated for patients in Qatar and those in India, and separate randomisation will be performed for males and females. Randomisation will be enclosed in sequentially numbered sealed envelopes (with separate envelopes for males and females). Patients will be allocated to either the treatment or control group.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of disease progression for mild cases</measure>
    <time_frame>28 days</time_frame>
    <description>Proportion hospitalised within 28 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evidence of disease progression in hospitalised patients (moderate and severe cases)</measure>
    <time_frame>28 days</time_frame>
    <description>Proportion requiring mechanical ventilation or dying within 28 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>28 days</time_frame>
    <description>Rate of mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital admission</measure>
    <time_frame>28 days</time_frame>
    <description>Length of stay at hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission to ICU/ HDU facility</measure>
    <time_frame>28 days</time_frame>
    <description>Length of stay at ICU/HDU facility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for renal replacement therapy</measure>
    <time_frame>28 days</time_frame>
    <description>Proportion requiring renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilation</measure>
    <time_frame>28 days</time_frame>
    <description>Proportion requiring mechanical ventilation within 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to being fit for hospital discharge</measure>
    <time_frame>28 days</time_frame>
    <description>Time of discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Oestrogen Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive standard care + transdermal 17ß-estradiol gel (3 mg) for ten days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive only standard care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal estradiol gel</intervention_name>
    <description>Patients will receive standard care +/- (randomsed 1:1) transdermal 17ß-estradiol gel (3 mg; applied to forearm, upper arm and shoulder) for ten days.</description>
    <arm_group_label>Oestrogen Therapy</arm_group_label>
    <other_name>oestrogel</other_name>
    <other_name>estrogel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute Covid-19 disease (PCR-confirmed or clinically diagnosed with high certainty)&#xD;
&#xD;
          -  Adult males &gt; 18 years of age OR&#xD;
&#xD;
          -  Post-menopausal women (spontaneous amenorrhoea for &gt;12 months in the absence of any&#xD;
             other cause)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Women:&#xD;
&#xD;
          -  taking oestrogen supplements or oestrogen receptor antagonists&#xD;
&#xD;
          -  with abnormal genital bleeding&#xD;
&#xD;
          -  with a history of breast cancer&#xD;
&#xD;
          -  with a history of endometrial or ovarian cancer&#xD;
&#xD;
          -  with untreated endometrial hyperplasia&#xD;
&#xD;
        Men:&#xD;
&#xD;
        • taking hormone therapies (e.g. for prostate cancer)&#xD;
&#xD;
        Any subject:&#xD;
&#xD;
          -  failure to obtain consent&#xD;
&#xD;
          -  taking lamotrigine&#xD;
&#xD;
          -  with a thromboembolic disorder (e.g. Protein C or Protein S deficiency, antithrombin&#xD;
             III deficiency)&#xD;
&#xD;
          -  with pre-existing liver or renal disease&#xD;
&#xD;
          -  with known allergy to exogenous oestrogens&#xD;
&#xD;
          -  with a history of porphyria&#xD;
&#xD;
          -  with a history of thromboembolic event including deep vein thrombosis, thromboembolic&#xD;
             stroke or pulmonary emboli&#xD;
&#xD;
          -  taking part in another interventional clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael P Frenneaux</last_name>
    <phone>0097455425733</phone>
    <email>MFrenneaux@hamad.qa</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adel Ganaw</last_name>
    <phone>0097433606110</phone>
    <email>aganaw@hamad.qa</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hamad Medical Corporation</name>
      <address>
        <city>Doha</city>
        <zip>PO Box 3050</zip>
        <country>Qatar</country>
      </address>
    </facility>
    <investigator>
      <last_name>Adel Ganaw, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael P Frenneaux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melanie Madhani, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hugh Montgomery, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Moad Ehfeda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ali Omrani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Muna Almaslamani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Qatar</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 6, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Oestrogen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

